+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Kidney Injury (AKI) Disease Treatment Market - Forecasts from 2019 to 2024

  • ID: 4835449
  • Report
  • July 2019
  • Region: Global
  • 100 pages
  • Knowledge Sourcing Intelligence LLP
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AM-Pharma
  • Angion Biomedica Corp.
  • AtoxBio
  • NIKKISO AMERICA, INC.
  • Thrasos Therapeutics Inc.
  • MORE
The acute kidney injury (AKI) disease treatment market is projected to grow at a CAGR of 1.10% to reach US$31.287 billion by 2024, from US$29.298 billion in 2018. The major drivers driving the growth of the global acute kidney injury (AKI) disease treatment market include growing elderly population, the prevalence of chronic diseases, and a growing number of acute care admissions and emergency department admissions leading to ICU admission. North America and Europe are expected to hold a significant market share due to the high disease prevalence and other chronic disease prevalence which may lead to the acute kidney disease while the Asia Pacific with Japan, having the maximum geriatric population in the world is expected to be the fastest growing. In addition, rising health awareness among people, especially in the developing countries will lead to frequent check-ups, emanating the market growth owing to early disease detection followed by treatment during the forecast period and beyond.

Major industry players profiled as part of the report are Exponential Biotherapies, Inc., NIKKISO AMERICA, INC., AM-Pharma, RenalGuard Solutions, Inc., Angion Biomedica Corp., Thrasos Therapeutics Inc., AtoxBio, and Sentien Biotechnologies, Inc.

Segmentation

The acute kidney injury (AKI) disease treatment market has been analyzed through following segments:

By Diagnosis

Urine Tests
Blood Tests
Glomerular Filtration Rate (GFR)
Imaging Tests
Kidney Biopsy

By Treatment

Dialysis
RenalGuard Therapy
Treatment for symptoms and complications

By Geography

North America
USA
Canada
Mexico

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AM-Pharma
  • Angion Biomedica Corp.
  • AtoxBio
  • NIKKISO AMERICA, INC.
  • Thrasos Therapeutics Inc.
  • MORE
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
4.5.1. By age group
4.5.2. By gender
4.5.3. By region
4.6. Product Pipeline
4.7. Innovations

5. ACUTE KIDNEY INJURY (AKI) DISEASE TREATMENT MARKET BY DIAGNOSIS
5.1. Urine Tests
5.2. Blood Tests
5.3. Glomerular Filtration Rate (GFR)
5.4. Imaging Tests
5.5. Kidney Biopsy

6. ACUTE KIDNEY INJURY (AKI) DISEASE TREATMENT MARKET BY TREATMENT
6.1. Dialysis
6.2. RenalGuard Therapy
6.3. Treatment for symptoms and complications

7. ACUTE KIDNEY INJURY (AKI) DISEASE TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others

8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES
9.1. Exponential Biotherapies, Inc.
9.2. NIKKISO AMERICA, INC.
9.3. AM-Pharma
9.4. RenalGuard Solutions, Inc.
9.5. Angion Biomedica Corp.
9.6. Thrasos Therapeutics Inc.
9.7. AtoxBio
9.8. Sentien Biotechnologies, Inc.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Exponential Biotherapies, Inc.
  • NIKKISO AMERICA, INC.
  • AM-Pharma
  • RenalGuard Solutions, Inc.
  • Angion Biomedica Corp.
  • Thrasos Therapeutics Inc.
  • AtoxBio
  • Sentien Biotechnologies, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll